For research use only. Not for therapeutic Use.
CaV1.3 antagonist-1 is a potent and highly selective CaV1.3 L-type calcium channel (LTCC) antagonist with an IC50 of 1.7 μM. CaV1.3 antagonist-1 inhibits CaV1.3 LTCC >600-fold more potently than CaV1.2 LTCC. CaV1.3 antagonist-1, a cyclopentyl derivative, has the potential for Parkinson’s disease research[1].
CaV1.3 antagonist-1 (Compound 8; 5 μM) exhibits 31.2% and 4.4% inhibition for CaV1.3 and CaV1.2 channel current in HEK293 cells, respectively. This correlates with the results of the FLIPR assay[1].
| Catalog Number | I025169 |
| CAS Number | 1391385-57-1 |
| Synonyms | 1-[2-(3-chlorophenyl)ethyl]-3-cyclopentyl-1,3-diazinane-2,4,6-trione |
| Molecular Formula | C17H19ClN2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H19ClN2O3/c18-13-5-3-4-12(10-13)8-9-19-15(21)11-16(22)20(17(19)23)14-6-1-2-7-14/h3-5,10,14H,1-2,6-9,11H2 |
| InChIKey | AJKSBVCOTKODMF-UHFFFAOYSA-N |
| SMILES | C1CCC(C1)N2C(=O)CC(=O)N(C2=O)CCC3=CC(=CC=C3)Cl |
| Reference | [1]. Soosung Kang, et al. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson’s disease. Nat Commun. 2012;3:1146. |
